
Quarterly ResultNov 5, 2026, 07:38 AM
Dyne Therapeutics Q3 Net Loss Widens to $193.6M; FDA Review Ongoing
AI Summary
Dyne Therapeutics announced its third quarter 2026 financial results, reporting a net loss of $193.6 million, or $1.06 per share, an increase from the prior year's loss. The company highlighted significant progress in its drug development pipeline, including its lead candidate z-rostudirsen for Duchenne muscular dystrophy (DMD), which is under FDA priority review with a target action date of January 21, 2027. Dyne also presented positive clinical data for z-basivarsen in myotonic dystrophy type 1 (DM1) and anticipates topline data from a key trial in Q1 2027. The company ended the quarter with $1.134 billion in cash and expects these reserves to fund operations into Q2 2028.
Key Highlights
- Dyne Therapeutics reported Q3 2026 net loss of $193.6 million, or $1.06 per share, compared to a net loss of $108.0 million, or $0.76 per share, in Q3 2025.
- Research and development expenses increased to $161.7 million in Q3 2026 from $97.2 million in Q3 2025.
- General and administrative expenses rose to $35.3 million in Q3 2026 from $16.7 million in Q3 2025.
- Cash, cash equivalents, and marketable securities were $1.134 billion as of September 30, 2026.
- Company expects cash reserves to fund operations into the second quarter of 2028.
- FDA priority review for z-rostudirsen BLA with PDUFA target action date of January 21, 2027.
- Additional one-year clinical data for z-basivarsen in DM1 presented, supporting clinical benefit.
- Topline data from ACHIEVE registrational expansion cohort for z-basivarsen planned for Q1 2027.
Price Impact
More from DYN